Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "SEC"

2373 News Found

Henkel, Covestro and Quad Industries collaborate for advanced medical wearables based on printed electronics
News | November 10, 2024

Henkel, Covestro and Quad Industries collaborate for advanced medical wearables based on printed electronics

Combined capabilities to drive novel healthcare applications presented at MEDICA 2024


Medanta to operate and manage 750 bed super speciality hospital in Pitampura, New Delhi
Healthcare | November 08, 2024

Medanta to operate and manage 750 bed super speciality hospital in Pitampura, New Delhi

Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years


JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
News | November 07, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth


KIMS to acquire 3,000 beds in next 5 years in Kerala
Healthcare | November 07, 2024

KIMS to acquire 3,000 beds in next 5 years in Kerala

The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode


Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
News | November 07, 2024

Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro

The company uses iPS cells to develop treatments for diseases relating to the kidney


Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
News | November 07, 2024

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

US Generics grew 5% to Rs. 467 Crores for the quarter


RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
News | November 07, 2024

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25


Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
News | November 06, 2024

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.


Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility
News | November 06, 2024

Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities


Imtiyaz Basade appointed Senior VP of NATCO Pharma
People | November 05, 2024

Imtiyaz Basade appointed Senior VP of NATCO Pharma

He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.